Does Menopausal Hormone Replacement Increase ADMH?
No, menopausal hormone replacement therapy (HRT) does not significantly increase acquired dermal melanocytic hyperpigmentation (melasma) in most women, though high-dose oral estrogen-only formulations may pose a small risk in darker-skinned individuals.
Evidence Quality and Interpretation
The available evidence on HRT and melasma is surprisingly limited, consisting primarily of case reports rather than robust clinical trials. The major menopause guidelines 1, 2 do not address melasma as a significant concern with HRT use, which itself suggests this is not a clinically meaningful problem in practice.
Risk Stratification by HRT Type
Low-Risk Formulations (Reassuring Evidence)
- Low-dose combined HRT and transdermal estrogen: A prospective study measuring actual pigmentation changes found no significant darkening of pre-existing hyperpigmented lesions after 3 months of low-dose HRT 3. This suggests standard-dose formulations used today are safe.
- Vaginal and topical estrogen: Minimal to no evidence of melasma association 4
- In vitro fertilization protocols: No reported cases of melasma 4
Higher-Risk Formulations (Caution Advised)
- High-dose oral estrogen-only therapy: The strongest documented association exists here, with case reports linking it to forearm melasma in women with Fitzpatrick skin types III-VI 4
- Combined oral HRT: Isolated case reports exist but evidence remains weak 4
Clinical Algorithm for Management
For women WITHOUT pre-existing melasma:
- Proceed with standard HRT formulations without specific melasma concerns
- Counsel on strict photoprotection (SPF 50+, broad-spectrum, daily reapplication)
- Consider transdermal over high-dose oral estrogen-only formulations in darker-skinned women (Fitzpatrick III-VI)
For women WITH pre-existing melasma:
- HRT is not contraindicated—the 2000 prospective study showed no worsening 3
- Emphasize that individual susceptibility and multiple factors beyond hormones drive melasma 3
- Prioritize transdermal or low-dose combined formulations over high-dose oral estrogen-only therapy
- Mandate rigorous photoprotection as the primary preventive measure
Important Caveats
The lack of robust data means we're extrapolating from limited evidence. The 2026 review explicitly states that "HRT-associated melasma is underrepresented in the literature" 4. However, decades of widespread HRT use without major melasma concerns in clinical practice suggests this is not a common or severe problem.
The key distinction: This is fundamentally different from pregnancy-associated melasma (chloasma), where hormonal effects are well-established. The lower, more physiologic doses used in modern HRT appear insufficient to trigger melasma in most women 3.
The absence of melasma discussion in major menopause guidelines 1, 2 that extensively detail other risks (breast cancer, cardiovascular disease, gallbladder disease) further supports that this is not a clinically significant concern warranting routine counseling or treatment modification.